Tristetraprolin regulates interleukin-6 expression through p38 MAPK-dependent affinity changes with mRNA 3′ untranslated region

Journal of Interferon and Cytokine Research

Volumn 31, Issue 8, 2011, Pages 629-637

  Zhao, Wenpu ^a   Liu, Min ^a   D'Silva, Nisha J ^a,b   Kirkwood, Keith L ^c  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; LUCIFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; SMALL INTERFERING RNA; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR ALPHA;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ARE2 GENE; ARE3 GENE; ARE4 GENE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FIBROBLAST; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HALF LIFE TIME; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE;

3' UNTRANSLATED REGIONS; ANIMALS; CELLS, CULTURED; FIBROBLASTS; INTERLEUKIN-6; MICE; MICE, KNOCKOUT; MUTAGENESIS, SITE-DIRECTED; MUTATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, SMALL INTERFERING; TRANSGENES; TRISTETRAPROLIN;

MUS;

EID: 80051499526     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2010.0154     Document Type: Article

References (43)

1. Adachi Y, Yoshio-Hoshino N, Nishimoto N. 2008. The blockade of IL-6 signaling in rational drug design. Curr Pharm Des 14(12):1217-1224. (Pubitemid 351997834)
2. Bakheet T, Williams BR, Khabar KS. 2003. ARED 2.0: An update of AU-rich element mRNA database. Nucleic Acids Res 31(1):421-423. (Pubitemid 36150418)
3. Carballo E, Cao H, Lai WS, Kennington EA, Campbell D, Blackshear PJ. 2001. Decreased sensitivity of tristetraprolindeficient cells to p38 inhibitors suggests the involvement of tristetraprolin in the p38 signaling pathway. J Biol Chem 276(45):42580-42587.
4. Carballo E, Lai WS, Blackshear PJ. 1998. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 281(5379):1001-1005. (Pubitemid 28399252)
5. Carballo E, Lai WS, Blackshear PJ. 2000. Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 95(6):1891-1899. (Pubitemid 30151623)
6. Chen CY, Gherzi R, Ong SE, Chan EL, Raijmakers R, Pruijn GJ, Stoecklin G, Moroni C, Mann M, Karin M. 2001. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell 107(4):451-464. (Pubitemid 33152781)
7. Hirano D, Nagashima M, Ogawa R, Yoshino S. 2001. Serum levels of interleukin 6 and stress related substances indicate mental stress condition in patients with rheumatoid arthritis. J Rheumatol 28(3):490-495. (Pubitemid 32202648)
8. Jiang Y, Mehta CK, Hsu TY, Alsulaimani FF. 2002. Bacteria induce osteoclastogenesis via an osteoblast-independent pathway. Infect Immun 70(6):3143-3148. (Pubitemid 34564177)
9. Johnson BA, Stehn JR, Yaffe MB, Blackwell TK. 2002. Cytoplasmic localization of tristetraprolin involves 14-3-3-dependent and -independent mechanisms. J Biol Chem 277(20):18029-18036. (Pubitemid 34967615)
10. Kastritis E, Charidimou A, Varkaris A, Dimopoulos MA. 2009. Targeted therapies in multiple myeloma. Target Oncol 4(1):23-36.
11. Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K. 2001. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 92(9):2399-2405. (Pubitemid 33029085)
12. Khabar KS. 2005. The AU-rich transcriptome: More than interferons and cytokines, and its role in disease. J Interferon Cytokine Res 25(1):1-10. (Pubitemid 40105586)
13. Khabar KS. 2007. Rapid transit in the immune cells: The role of mRNA turnover regulation. J Leukoc Biol 81(6):1335-1344. (Pubitemid 46827957)
14. Khabar KS. 2010. Post-transcriptional control during chronic inflammation and cancer: A focus on AU-rich elements. Cell Mol Life Sci 67(17):2937-2955.
15. Khabar KS, Bakheet T, Williams BR. 2005. AU-rich transient response transcripts in the human genome: expressed sequence tag clustering and gene discovery approach. Genomics 85(2):165-175. (Pubitemid 40164782)
16. Kirkwood KL, Li F, Rogers JE, Otremba J, Coatney DD, Kreider JM, D'Silva NJ, Chakravarty S, Dugar S, Higgins LS, Protter AA, Medicherla S. 2007. A p38alpha selective mitogenactivated protein kinase inhibitor prevents periodontal bone loss. J Pharmacol Exp Ther 320(1):56-63. (Pubitemid 46025719)
17. Kotlyarov A, Gaestel M. 2002. Is MK2 (mitogen-activated protein kinase-activated protein kinase 2) the key for understanding post-transcriptional regulation of gene expression? Biochem Soc Trans 30(Pt 6):959-963. (Pubitemid 36002388)
18. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, Blackshear PJ. 1999. Evidence that tristetraprolin binds to AUrich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 19(6):4311-4323. (Pubitemid 29242006)
19. Li Q Yu H, Zinna R, Martin K, Herbert B, Liu A, Rossa C, Jr., Kirkwood KL. 2011. Silencing MAP kinase-activated protein kinase-2 arrests inflammatory bone loss. J Pharmacol Exp Ther 336(3):633-642.
20. Lykke-Andersen J, Wagner E. 2005. Recruitment and activation of mRNA decay enzymes by two ARE-mediated decay activation domains in the proteins TTP and BRF-1. Genes Dev 19(3):351-361. (Pubitemid 40189298)
21. Mahtani KR, Brook M, Dean JL, Sully G, Saklatvala J, Clark AR. 2001. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol Cell Biol 21(19):6461-6469. (Pubitemid 32927414)
22. Nishimoto N. 2010. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther 87(4):483-487.
23. Patil C, Rossa C, Jr., Kirkwood KL. 2006. A. actinomycetemcomitans LPS induces IL-6 expression through multiple MAPK pathways in periodontal ligament fibroblasts. Oral Microbiol Immunol 21(6):392-398.
24. Patil C, Zhu X, Rossa C, Jr., Kim YJ, Kirkwood KL. 2004. p38 MAPK regulates IL-1beta induced IL-6 expression through mRNA stability in osteoblasts. Immunol Invest 33(2):213-233. (Pubitemid 38685932)
25. Patil CS, Kirkwood KL. 2007. p38 MAPK signaling in oral-related diseases. J Dent Res 86(9):812-825.
26. Patil CS, Liu M, Zhao W, Coatney DD, Li F, VanTubergen EA, D'Silva NJ, Kirkwood KL. 2008. Targeting mRNA stability arrests inflammatory bone loss. Mol Ther 16(10):1657-1664.
27. Raineri I, Wegmueller D, Gross B, Certa U, Moroni C. 2004. Roles of AUF1 isoforms, HuR and BRF1 in ARE-dependent mRNA turnover studied by RNA interference. Nucleic Acids Res 32(4):1279-1288. (Pubitemid 38854729)
28. Rigby WF, Roy K, Collins J, Rigby S, Connolly JE, Bloch DB, Brooks SA. 2005. Structure/function analysis of tristetraprolin (TTP): P38 stress-activated protein kinase and lipopolysaccharide stimulation do not alter TTP function. J Immunol 174(12):7883-7893. (Pubitemid 40806298)
29. Rossa C, Jr., Ehman K, Liu M, Patil C, Kirkwood K. 2006. MKK3/6-p38MAPK signaling is required for IL-1b And TNF-a induced RANKL expression in bone marrow stromal cells. J Interferon Cytokine Res 26(10):719-729. (Pubitemid 44934111)
30. Rossa C, Jr., Liu M, Kirkwood KL. 2008. A dominant function of p38 mitogen-activated protein kinase signaling in receptor activator of nuclear factor-kappaB ligand expression and osteoclastogenesis induction by Aggregatibacter actinomycetemcomitans and Escherichia coli lipopolysaccharide. J Periodontal Res 43(2):201-211.
31. Sandler H, Stoecklin G. 2008. Control of mRNA decay by phosphorylation of tristetraprolin. Biochem Soc Trans 36(Pt 3): 491-496. (Pubitemid 351839361)
32. Stoecklin G, Colombi M, Raineri I, Leuenberger S, Mallaun M, Schmidlin M, Gross B, Lu M, Kitamura T, Moroni C. 2002. Functional cloning of BRF1, a regulator of ARE-dependent mRNA turnover. EMBO J 21(17):4709-4718. (Pubitemid 34984358)
33. Stoecklin G, Gross B, Ming XF, Moroni C. 2003. A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA. Oncogene 22(23):3554-3561. (Pubitemid 36765315)
34. Stoecklin G, Stubbs T, Kedersha N, Wax S, Rigby WF, Blackwell TK, Anderson P. 2004. MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J 23(6):1313-1324. (Pubitemid 38525003)
35. Sully G, Dean JL, Wait R, Rawlinson L, Santalucia T, Saklatvala J, Clark AR. 2004. Structural and functional dissection of a conserved destabilizing element of cyclo-oxygenase-2 mRNA: evidence against the involvement of AUF-1 [AU-rich element/ poly(U)-binding/degradation factor-1], AUF-2, tristetraprolin, HuR (Hu antigen R) or FBP1 (far-upstream-sequence-elementbinding protein 1). Biochem J 377(Pt 3):629-639. (Pubitemid 38221834)
36. Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD, Schenkman DI, Gilkeson GS, Broxmeyer HE, Haynes BF, Blackshear PJ. 1996. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 4(5):445-454. (Pubitemid 26354654)
37. Van Tubergen E, Vander Broek R, Lee J, Wolf G, Carey T, Bradford C, Prince M, Kirkwood KL, D'Silva NJ. 2010. Tristetraprolin regulates IL-6 which is correlated with tumor progression in head and neck squamous cell carcinoma. Cancer, 2011; DOI: 10.1002/cncr.25859.
38. Varnum BC, Ma QF, Chi TH, Fletcher B, Herschman HR. 1991. The TIS11 primary response gene is a member of a gene family that encodes proteins with a highly conserved sequence containing an unusual Cys-His repeat. Mol Cell Biol 11(3):1754-1758. (Pubitemid 21895539)
39. Waldner MJ, Neurath MF. 2008. Cytokines in colitis associated cancer: Potential drug targets? Inflamm Allergy Drug Targets 7(3):187-194.
40. Winzen R, Kracht M, Ritter B, Wilhelm A, Chen CY, Shyu AB, Muller M, Gaestel M, Resch K, Holtmann H. 1999. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J 18(18):4969-4980. (Pubitemid 29443799)
41. Yoshio-Hoshino N, Adachi Y, Aoki C, Pereboev A, Curiel DT, Nishimoto N. 2007. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res 67(3):871-875.
42. Zhao W, Liu M, Kirkwood KL. 2008. p38alpha stabilizes interleukin-6 mRNA via multiple AU-rich elements. J Biol Chem 283(4):1778-1785.
43. Zhu W, Brauchle MA, Di Padova F, Gram H, New L, Ono K, Downey JS, Han J. 2001. Gene suppression by tristetraprolin and release by the p38 pathway. Am J Physiol Lung Cell Mol Physiol 281(2):L499-L508.